Answers are grounded in this paper and cite their sources.
Narrative review demonstrates cefepime/enmetazobactam's efficacy for complicated urinary tract infections, indicating potential in AMR management.
Introduction: Antimicrobial Resistance (AMR) among gram-negative pathogens poses a major global threat, with limited new antibacterials approved. Cefepime/ enmetazobactam, a novel β-lactam/β-lactamase inhibitor, restores cefepime activity against extendedspectrum β-lactamase (ESBL)-producing Enterobacterales and other multidrug-resistant gramnegatives, offering an option for complicated Urinary Tract Infections (cUTIs). Methods: This narrative review synthesises phase 1–3 trials, in vitro surveillance, pharmacokinetic data, and network meta-analyses on cefepime/enmetazobactam versus comparators in cUTIs and related infections. Results: Enmetazobactam inactivates class A β-lactamases (KPC-2, CTX-M-15, SHV-1), boosting cefepime susceptibility from 2% to 98% against ESBL-Enterobacterales; activity is robust against AmpC-producers but limited against metallo-β-lactamases, OXA-types, Acinetobacter baumannii, and Stenotrophomonas maltophilia. In the phase 3 ALLIUM trial (n=1034), cefepime/enmetazobactam achieved superior composite cure rates versus piperacillin/ tazobactam (79.1% vs 58.9%; difference 21.2%) in cUTIs/pyelonephritis, including ESBLsubgroups. Network meta-analyses confirm outcomes comparable to carbapenems, with similar safety (mainly hepatic/infusion events). Discussion: Cefepime/enmetazobactam shows favourable outcomes as a newer agent for ESBLcUTIs compared to piperacillin/tazobactam, although evidence remains cUTI-focused with modest ESBL representation and spectrum gaps against key resistant pathogens. Pathogendirected use within stewardship is essential. Conclusion: Cefepime/enmetazobactam may contribute to AMR management for susceptible cUTIs/pyelonephritis and HAP/VAP, but its role beyond these indications will depend on further trials in high-risk ESBL/carbapenemase infections.
No takes yet. Share an insight, caveat, or question.
P et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: